In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of C4 Therapeutics Inc (NASDAQ: CCCC) closed at $1.91 in the last session, down -2.55% from day before closing price of $1.96. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 0.92 million shares were traded. CCCC stock price reached its highest trading level at $1.96 during the session, while it also had its lowest trading level at $1.9.
Ratios:
We take a closer look at CCCC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.76 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.36.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $8.
Stephens Upgraded its Equal-Weight to Overweight on September 15, 2025, while the target price for the stock was maintained at $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 185106528 and an Enterprise Value of 54685540. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.15 while its Price-to-Book (P/B) ratio in mrq is 0.92. Its current Enterprise Value per Revenue stands at 1.816 whereas that against EBITDA is -0.467.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.92, which has changed by -0.5127551 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $4.26, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -20.29%, while the 200-Day Moving Average is calculated to be -8.03%.
Shares Statistics:
According to the various share statistics, CCCC traded on average about 2.03M shares per day over the past 3-months and 2189590 shares per day over the past 10 days. A total of 96.91M shares are outstanding, with a floating share count of 78.37M. Insiders hold about 19.13% of the company’s shares, while institutions hold 57.44% stake in the company. Shares short for CCCC as of 1765756800 were 7172653 with a Short Ratio of 3.53, compared to 1763078400 on 4848155. Therefore, it implies a Short% of Shares Outstanding of 7172653 and a Short% of Float of 7.8200005.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of C4 Therapeutics Inc (CCCC) in the stock market.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.33 and -$1.71 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$1.15 and -$1.55.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $4.48M. It ranges from a high estimate of $8M to a low estimate of $100k. As of. The current estimate, C4 Therapeutics Inc’s year-ago sales were $5.18M
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $35M, while the lowest revenue estimate was $25M, resulting in an average revenue estimate of $30.39M. In the same quarter a year ago, actual revenue was $35.58M
